7,736.89

+14.29

+0.19%

52,520.15

+142.58

+0.27%

26,471.36

-6.45

-0.02%

2,816.18

-2.69

-0.10%

5.03

+0.04

+0.74%

17.26

-0.26

-1.48%

4,057.00

-17.60

-0.43%

80,607.57

+173.39

+0.22%

Crude Oil Dec 26

102.32

+2.42

+2.42%

US Private Equity

10,931.50

+19.85

+0.18%

NasdaqGS - Nasdaq Real Time Price USD

Stoke Therapeutics, Inc. (STOK)

26.43 +0.30 (+1.15%)

As of 11:26:06 AM EDT. Market Open.

Trade STOK on Coinbase

Loading Chart for STOK

Chart Range Bar

Interval:

In partnership with ChartIQ

Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

Mobilize your Website

View Site in Mobile | Classic

Share by: